Clinical Trial: NCT04778579
Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy
Status:
UNKNOWNPhase:
Phase 2| Lead Sponsor: | Sara V. Latorre |
| Information Provided By: | Institut d'Investigacions Biomèdiques August Pi i Sunyer |
| Last Update Posted: | 2024-06-26 |
Study Overview
Brief Summary
To assess the efficacy (in terms of response rate and duration) of the infusion of ARI-0001 cells (Adult differentiated autologous T-cells from peripheral blood, expanded and transducted with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity [A3B1] conjugated to the 4-aBB and CD3z co-stimulatory regions) in patients with resistant or refractory CD19+ acute lymphoid leukemia
Official Title
Conditions
Intervention / Treatment
- Drug: ARI-0001 cells
Other Study ID Numbers
- CART19-BE-02
Start Date (Actual)
Primary Completion Date (Estimated)
Study Completion Date (Estimated)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Sara V. Latorre |
| Information Provided By: | Institut d'Investigacions Biomèdiques August Pi i Sunyer |
| Last Update Posted: | 2024-06-26 |
Study Overview
Brief Summary
To assess the efficacy (in terms of response rate and duration) of the infusion of ARI-0001 cells (Adult differentiated autologous T-cells from peripheral blood, expanded and transducted with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity [A3B1] conjugated to the 4-aBB and CD3z co-stimulatory regions) in patients with resistant or refractory CD19+ acute lymphoid leukemia
Official Title
Conditions
Intervention / Treatment
- Drug: ARI-0001 cells
Other Study ID Numbers
- CART19-BE-02